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In The Lancet, David Mendelow and colleagues1 report 
the results of their second randomised STICH (STICH II) 
trial of early surgery compared with initial conservative 
treatment for patients with superﬁ cial lobar intra-
cerebral haemorrhage. They included 597 patients from 
78 centres in 27 countries; 589 of 597 patients were 
available for follow-up at 6 months. The investigators 
did not ﬁ nd signiﬁ cant evidence to support the 
hypothesis that early surgery improves outcome in 
conscious patients with a superﬁ cial intracerebral 
haemor rhage with a volume of 10–100 mL, and found 
no evidence of additional intraventricular haemorrhage.
The results, however, imply that early surgery might 
have a small, yet clinically relevant, survival advantage 
in the subgroup of patients with a poor prognostic score 
or in patients whose neurological status progressively 
deteriorates. This score (10 × Glasgow Coma Scale 
[GCS] – age [years] – 0·64 × volume [mL]) with a cutoﬀ  
of 27·672 to diﬀ erentiate between patients with a 
good prognosis (score greater than 27·672) and those 
with a poor prognosis, has already been reported in the 
ﬁ rst STICH trial.2 The notion that early surgery might 
be beneﬁ cial in this subgroup of patients is supported 
by the results of the investigators’ updated meta-
analysis of 15 trials, including a total of 1695 patients 
in the surgery group and 1671 patients in the initial 
conservative treatment group. The overall result of 
this meta-analysis of patients with diﬀ erent types of 
intracerebral haemorrhage favours surgery (Peto odds 
ratio 0·74, 95% CI 0·64–0·86).
The STICH II results show that 38% of patients assigned 
to initial conservative treatment had a favour able 
outcome compared with 41% assigned to early surgery. 
As frequently noted in surgical ran dom ised controlled 
trials, the STICH II trial had a high crossover rate of 21% 
from initial conservative treat ment to delayed surgery 
versus a rather low crossover rate of 4% from early 
surgery to conservative treatment. This diﬀ erence could 
lead to a potential underestimation of the true beneﬁ t of 
delayed surgery as a treatment option for patients with 
superﬁ cial lobar intracerebral haemorrhage. However, 
taking into account the well known risks of procedure-
related morbidity in surgically treated patients, the results 
of STICH II indicate that an initially conservative approach 
might be indicated in patients with a good prognostic 
score. Moreover, according to the ethical principle of 
primum nihil nocere, for patients with a GCS of 14 or 15, 
with no or only minor deﬁ cits and a small intracerebral 
haemorrhage, surgery should not be recommended.
With this renaissance of interest in the role of 
surgery for the treatment of patients with intracerebral 
haemorrhage, the results of the CLEAR III3 and 
MISTIE III4 studies using minimally invasive procedures 
are eagerly awaited. In the CLEAR III trial, the accelerated 
resolution of intraventricular haemorrhage is being 
assessed to ascertain the beneﬁ t of recombinant tissue 
plasminogen activator with clot removal, whereas 
in MISTIE III the eﬀ ect of minimally invasive surgery 
plus recombinant tissue plasminogen activator is 
being investigated in the treatment of intra cerebral 
haemorrhage. Additionally, decompressive hemi crani-
ectomy might be a promising surgical pro cedure for 
patients with intracerebral haemorrhage.5
In conclusion, the STICH II investigators and all par-
tici pating centres should be commended for their 
extensive and labour-intensive work. Continuing inter-
disciplinary research is of paramount importance 
for further develop ment of evidence-based treatment 
guide lines for patients with intracerebral haemorrhage, 
based on neuro logical status, haematoma characteris-
tics (volume, depth, location, and presence and extent 
of perilesional oedema), comorbidities, and genetic 
characteristics (eg, apoli po protein E status).6,7 These 
guide lines are essential to determine which patients 
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Consensus on the management of diabetes mellitus in 
older people has recommended an HbA1c target range of 
7·0–7·5% (53–59 mmol/mol).1,2 The American Diabetes 
Association and European Association for the Study 
of Diabetes recommend that in frail people the goal 
should be 7·5–8·0% (59–64 mmol/mol) or possibly even 
slightly higher, although they have not deﬁ ned how 
frailty should be assessed.2 The hazards of aggressive 
treatment in older people with diabetes are now well 
recognised.3 An HbA1c concentration of around 7·5% 
(59 mmol/mol) is in keeping with a UK General Practice 
Research Database retrospective study which reported 
that the HbA1c concentration associated with the lowest 
hazard for all-cause mortality was 7·5% (59 mmol/mol).4
In patients with frailty and comorbidity, aggres-
sive therapy of disease states and associated poly phar-
macy need to be reduced; eﬀ orts should be focused on 
decreasing sarcopenia with therapeutic exercise and 
possibly enhanced protein intake.5 This approach is in 
keeping with Yao and colleagues’ ﬁ ndings,6 which suggest 
that, in frail elderly people, an HbA1c concentration 
between 8% and 8·9% (64–74 mmol/mol) was most 
eﬀ ective at slowing physical decline. An international 
consortium of geriatric medicine societies has suggested 
that all people aged 70 years or older should be screened 
for frailty with a simple questionnaire that assists 
diagnosis in objective terms, and that therapy should be 
appropriately tailored to those who are identiﬁ ed as frail.7
In The Lancet, David Strain and colleagues8 report the 
results of a controlled trial in which they attempted 
to individualise treatment in older people with 
type 2 diabetes on the basis of age, frailty status, 
comorbidities, and baseline HbA1c. 278 patients were 
randomly assigned to treatment with vildagliptin or 
placebo, and eﬃ  cacy was assessed at 24 weeks in terms 
of: the proportion of patients reaching individualised 
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will beneﬁ t from which treatment (conservative, open 
surgical, or minimally invasive) to improve outcome in 
terms of reduction of mortality and morbidity.
So far, the best evidence available is derived from 
STICH II, although overall the evidence is insuﬃ  cient. 
Therefore, joint future eﬀ orts are mandatory to trans-
late current and future evidence into clinical prac tice, and 
such research could have many practical impli cations for 
hospital admis sion policies and for the overall manage-
ment of patients with intracerebral haemorrhage.
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